Jiangxi Rimag Group Co., Ltd.

SEHK:2522 Stock Report

Market Cap: HK$18.0b

Jiangxi Rimag Group Valuation

Is 2522 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2522 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2522 (HK$50.45) is trading above our estimate of fair value (HK$47.89)

Significantly Below Fair Value: 2522 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2522?

Key metric: As 2522 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2522. This is calculated by dividing 2522's market cap by their current revenue.
What is 2522's PS Ratio?
PS Ratio20.6x
SalesCN¥812.85m
Market CapCN¥16.73b

Price to Sales Ratio vs Peers

How does 2522's PS Ratio compare to its peers?

The above table shows the PS ratio for 2522 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.8x
2273 Gushengtang Holdings
2.8x24.7%HK$8.2b
1951 Jinxin Fertility Group
2.6x10.8%HK$8.1b
6606 New Horizon Health
4.3x20.5%HK$6.3b
9860 Adicon Holdings
1.4x9.0%HK$4.5b
2522 Jiangxi Rimag Group
20.6x30.0%HK$18.0b

Price-To-Sales vs Peers: 2522 is expensive based on its Price-To-Sales Ratio (20.6x) compared to the peer average (2.8x).

Price to Sales Ratio vs Industry

How does 2522's PS Ratio compare vs other companies in the HK Healthcare Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
1099 Sinopharm Group
0.1x5.8%US$8.04b
9885 YSB
0.2xn/aUS$505.51m
2289 Charmacy Pharmaceutical
0.2xn/aUS$128.47m
9955 ClouDr Group
0.2x23.5%US$90.50m
2522 20.6xIndustry Avg. 0.9xNo. of Companies11PS012345+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2522 is expensive based on its Price-To-Sales Ratio (20.6x) compared to the Hong Kong Healthcare industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is 2522's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2522 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 2522's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sinopharm Group

HK$62.6b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.05

7D

-0.7%

1Y

0.3%

OrbusNeich Medical Group Holdings

HK$3.4b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

6929

HK$4.10

7D

-5.7%

1Y

-48.6%

Hygeia Healthcare Holdings

HK$10.2b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.40

7D

-6.6%

1Y

-66.9%